HIV molecular immunology database

 

Search the Epitope Variant and Escape Mutation Database

Help


Found 1 matching record:

Displaying record number 54498

HXB2 Location  Gag(77-85)   Gag Epitope Map
View variants at this location
Epitope SLYNTVATL   Epitope Alignment
Variants
SLYNTiATL   non-susceptible form; susceptible form
SLYNTVAvL   observed variant
SLfNTVAvL   escape documented in this paper
SLfNTVATL   diminished HLA binding or increased off-rate; susceptible form
SLfNTiATL   diminished response
SLfNTiAvL   escape documented in this paper; TCR related mutation
SLhNaVAvL   susceptible form
SLYNTiAvL   diminished response
SLYNTiAiL   observed variant
SLfNTVATv   susceptible form
SLYNaVATL   susceptible form
SLYNlVAvL   diminished HLA binding or increased off-rate
SLYNTVAif   diminished HLA binding or increased off-rate
SLfNaVATL   reversion; susceptible form
SLfNaVAvL   susceptible form
SLfNmVATL   susceptible form
SLYNTVsTL   susceptible form
SLYNTitvL   susceptible form
SLYNTisvL   susceptible form
Epitope Name SL9
Species (MHC/HLA human(A2)

Variant Details

Showing all: 19 variant(s).


Variant ID.  467
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTiATL
Mutations V/I
Epitope Location V6I
HXB2 Location V82I
Mutation Type NSF: non-susceptible form
SF: susceptible form
Note Variant present in 8% of 76 A2+ patients. Bound strongly to HLA-A2 (binding affinity was 94 nM). Was recognized by some A2+ patient's PBMCs and not recognized by others.


Variant ID.  468
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTVAvL
Mutations T/V
Epitope Location T8V
HXB2 Location T84V
Mutation Type OV: observed variant
Note Variant present in 4% of A2+ patients. Bound strongly to HLA-A2 (binding affinity was 20 nM). Was not present in the patients tested for EliSpot responses.


Variant ID.  469
Epitope Seq.  SLYNTVATL
Variant Seq.  SLfNTVAvL
Mutations Y/F T/V
Epitope Location Y3F T8V
HXB2 Location Y79F T84V
Mutation Type E: escape documented in this paper
Note Positively selected transition variant present in 5% of A2+ patients. HLA-binding affinity was sufficient to elicit CTL responses. Not well recognized by patient PBMCs.


Variant ID.  470
Epitope Seq.  SLYNTVATL
Variant Seq.  SLfNTVATL
Mutations Y/F
Epitope Location Y3F
HXB2 Location Y79F
Mutation Type DHB: diminished HLA binding or increased off-rate
SF: susceptible form
Note Positively selected transition variant present in 16% of A2+ patients. HLA-binding affinity was sufficient to elicit CTL responses but was somewhat weaker compared to other variants. Recognized by patient PBMCs.


Variant ID.  471
Epitope Seq.  SLYNTVATL
Variant Seq.  SLfNTiATL
Mutations Y/F V/I
Epitope Location Y3F V6I
HXB2 Location Y79F V82I
Mutation Type DR: diminished response
Note Transition variant present in 7% of A2+ patients. Intermediate recognition by patient PBMCs.


Variant ID.  472
Epitope Seq.  SLYNTVATL
Variant Seq.  SLfNTiAvL
Mutations Y/F V/I T/V
Epitope Location Y3F V6I T8V
HXB2 Location Y79F V82I T84V
Mutation Type E: escape documented in this paper
TCR: TCR related mutation
Note Positively selected escape variant present in 7% of A2+ patients. HLA-binding affinity was sufficient to elicit CTL responses but the responses were usually weaker than to other variants. Assumed to impair TCR binding.


Variant ID.  473
Epitope Seq.  SLYNTVATL
Variant Seq.  SLhNaVAvL
Mutations Y/H T/A T/V
Epitope Location Y3H T5A T8V
HXB2 Location Y79H T81A T84V
Mutation Type SF: susceptible form
Note A minor variant found in one patient. HLA-binding affinity was sufficient to elicit CTL responses.


Variant ID.  474
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTiAvL
Mutations V/I T/V
Epitope Location V6I T8V
HXB2 Location V82I T84V
Mutation Type DR: diminished response
Note Positively selected transition variant present in 11% of A2+ patients. HLA-binding affinity was sufficient to elicit CTL responses. Not well recognized by patient PBMCs.


Variant ID.  475
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTiAiL
Mutations V/I T/I
Epitope Location V6I T8I
HXB2 Location V82I T84I
Mutation Type OV: observed variant
Note A minor variant found in one patient.


Variant ID.  476
Epitope Seq.  SLYNTVATL
Variant Seq.  SLfNTVATv
Mutations Y/F L/V
Epitope Location Y3F L9V
HXB2 Location Y79F L85V
Mutation Type SF: susceptible form
Note A minor variant found in one patient. HLA-binding affinity was sufficient to elicit CTL responses.


Variant ID.  477
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNaVATL
Mutations T/A
Epitope Location T5A
HXB2 Location T81A
Mutation Type SF: susceptible form
Note A minor variant found in one patient. HLA-binding affinity was sufficient to elicit CTL responses.


Variant ID.  478
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNlVAvL
Mutations T/L T/V
Epitope Location T5L T8V
HXB2 Location T81L T84V
Mutation Type DHB: diminished HLA binding or increased off-rate
Note A minor variant found in one patient. HLA-binding affinity was not sufficient to elicit CTL responses.


Variant ID.  479
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTVAif
Mutations T/I L/F
Epitope Location T8I L9F
HXB2 Location T84I L85F
Mutation Type DHB: diminished HLA binding or increased off-rate
Note A minor variant found in one patient. HLA-binding affinity was not sufficient to elicit CTL responses.


Variant ID.  480
Epitope Seq.  SLYNTVATL
Variant Seq.  SLfNaVATL
Mutations Y/F T/A
Epitope Location Y3F T5A
HXB2 Location Y79F T81A
Mutation Type R: reversion
SF: susceptible form
Note An unusual variant resulting in strong response. This is suggested to be a transient reversion variant. HLA-binding affinity was sufficient to elicit CTL responses.


Variant ID.  481
Epitope Seq.  SLYNTVATL
Variant Seq.  SLfNaVAvL
Mutations Y/F T/A T/V
Epitope Location Y3F T5A T8V
HXB2 Location Y79F T81A T84V
Mutation Type SF: susceptible form
Note A minor variant found in one patient. HLA-binding affinity was sufficient to elicit CTL responses.


Variant ID.  482
Epitope Seq.  SLYNTVATL
Variant Seq.  SLfNmVATL
Mutations Y/F T/M
Epitope Location Y3F T5M
HXB2 Location Y79F T81M
Mutation Type SF: susceptible form
Note A minor variant found in one patient. HLA-binding affinity was sufficient to elicit CTL responses.


Variant ID.  483
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTVsTL
Mutations A/S
Epitope Location A7S
HXB2 Location A83S
Mutation Type SF: susceptible form
Note Variant described before. HLA-binding affinity was sufficient to elicit CTL responses.


Variant ID.  484
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTitvL
Mutations V/I A/T T/V
Epitope Location V6I A7T T8V
HXB2 Location V82I A83T T84V
Mutation Type SF: susceptible form
Note Variant described before. HLA-binding affinity was sufficient to elicit CTL responses.


Variant ID.  485
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTisvL
Mutations V/I A/S T/V
Epitope Location V6I A7S T8V
HXB2 Location V82I A83S T84V
Mutation Type SF: susceptible form
Note Variant described before. HLA-binding affinity was sufficient to elicit CTL responses.

References

Iversen2006 Astrid K. N. Iversen, Guillaume Stewart-Jones, Gerald H. Learn, Natasha Christie, Christina Sylvester-Hviid, Andrew E. Armitage, Rupert Kaul, Tara Beattie, Jean K. Lee, Yanping Li, Pojchong Chotiyarnwong, Tao Dong, Xiaoning Xu, Mark A. Luscher, Kelly MacDonald, Henrik Ullum, Bente Klarlund-Pedersen, Peter Skinhøj, Lars Fugger, Søren Buus, James I. Mullins, E. Yvonne Jones, P. Anton van der Merwe, and Andrew J. McMichael. Conflicting Selective Forces Affect T Cell Receptor Contacts in an Immunodominant Human Immunodeficiency Virus Epitope. Nat. Immunol., 7(2):179-189, Feb 2006. PubMed ID: 16388312. Show all entries for this paper.


Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health